We retrieved the co-expressed gene list of each of CDC20, RRM2, and DTL across ADPC, CRPC, and NEPC cohorts, which showed 175, 92, and 159 genes significantly co-expressed with CDRs at different prostate cancer stages, respectively (Fig. 4A–F; Fig. S6). This evidence concerns the gene RRM2 and prostate carcinoma.